Mostrar el registro sencillo del ítem

Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue

dc.rights.licenseopenen_US
dc.contributor.authorLAPIDARI, Pietro
dc.contributor.authorDJEHAL, Nardjes
dc.contributor.authorHAVAS, Julie
dc.contributor.authorGBENOU, Arnauld
dc.contributor.authorMARTIN, Elise
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHARLES, Cecile
dc.contributor.authorDAUCHY, Sarah
dc.contributor.authorPISTILLI, Barbara
dc.contributor.authorCADEAU, Claire
dc.contributor.authorBERTAUT, Aurelie
dc.contributor.authorEVERHARD, Sibille
dc.contributor.authorMARTIN, Anne Laure
dc.contributor.authorCOUTANT, Charles
dc.contributor.authorCOTTU, Paul
dc.contributor.authorMENVIELLE, Gwenn
dc.contributor.authorDUMAS, Agnes
dc.contributor.authorANDRE, Fabrice
dc.contributor.authorMICHIELS, Stefan
dc.contributor.authorVAZ-LUIS, Ines
dc.contributor.authorDI MEGLIO, Antonio
dc.date.accessioned2021-12-06T13:44:06Z
dc.date.available2021-12-06T13:44:06Z
dc.date.issued2021-09-24
dc.identifier.issn1573-7217 (Electronic) 0167-6806 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/123992
dc.description.abstractEnBACKGROUND: Despite the questionable effectiveness of oral complementary and alternative medicine (OCAM) in relieving cancer-related symptoms, including fatigue (CRF), many patients use it aiming to improve their quality of life. We assessed factors associated with OCAM use, focusing on CRF. METHODS: Women with stage I-III breast cancer (BC) were included from CANTO (NCT01993498). OCAM use was defined as taking homeopathy, vitamins/minerals, or herbal/dietary supplements. Multivariable multinomial logistic regressions evaluated associations of CRF (EORTC QLQ-C30), patient, and treatment characteristics with OCAM use. RESULTS: Among 5237 women, 23.0% reported OCAM use overall (49.3% at diagnosis, 50.7% starting post-diagnosis), mostly homeopathy (65.4%). Mean (SD) CRF score was 27.6 (24.0) at diagnosis and 35.1 (25.3) at post-diagnosis. More intense CRF was consistently associated with OCAM use at diagnosis and post-diagnosis [adjusted odds ratio (aOR) for 10-point increase 1.05 (95% Confidence interval 1.01-1.09) and 1.04 (1.01-1.09) vs. never use, respectively]. Odds of using OCAM at diagnosis were higher among older [for 5-year increase, 1.09 (1.04-1.14)] and more educated patients [college vs. primary 1.80 (1.27-2.55)]. Women with income > 3000 [vs. < 1500 euros/month, 1.44 (1.02-2.03)], anxiety [vs. not, 1.25 (1.01-1.54)], and those receiving chemotherapy [vs. not, 1.32 (1.04-1.68)] had higher odds of using OCAM post-diagnosis. CONCLUSION: One-in-four patients reported use of OCAM. More severe CRF was consistently associated with its use. Moreover, older, better educated, wealthier, more anxious women, and those receiving chemotherapy seemed more prone to use OCAM. Characterizing profiles of BC patients more frequently resorting to OCAM may help deliver targeted information about its benefits and potential risks.
dc.description.sponsorshipEtude des toxicités chroniques des traitements anticancéreux chez les patientes porteuses canceren_US
dc.language.isoENen_US
dc.subject.enEarly breast cancer
dc.subject.enSurvivorship
dc.subject.enComplementary and alternative medicine
dc.subject.enCancer-related fatigue
dc.subject.enCohort study
dc.title.enDeterminants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s10549-021-06394-2en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34559354en_US
bordeaux.journalBreast Cancer Research and Treatmenten_US
bordeaux.page517-529en_US
bordeaux.volume190en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMRISPen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de la Rechercheen_US
hal.identifierhal-03467344
hal.version1
hal.date.transferred2021-12-06T13:44:09Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Breast%20Cancer%20Research%20and%20Treatment&amp;rft.date=2021-09-24&amp;rft.volume=190&amp;rft.issue=3&amp;rft.spage=517-529&amp;rft.epage=517-529&amp;rft.eissn=1573-7217%20(Electronic)%200167-6806%20(Linking)&amp;rft.issn=1573-7217%20(Electronic)%200167-6806%20(Linking)&amp;rft.au=LAPIDARI,%20Pietro&amp;DJEHAL,%20Nardjes&amp;HAVAS,%20Julie&amp;GBENOU,%20Arnauld&amp;MARTIN,%20Elise&amp;rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem